On the other hand, depletion of DE Tfh cells via <i>Ezh2</i> gene deletion, inhibition of EZH2 (using FDA-approved drug, tazemetostat), or anti-CXCR6 mAb led to tumor regression. The gene discussed is EZH2; the disease is neoplasm.